Tag: cancer cell

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line...

— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsCancer cell

REE Automotive Receives Nasdaq Minimum Bid Price Notification

Dalai Lama’s 90th: A Global Celebration of Compassion, Peace, and Wisdom

Hope Regional Cancer Center Earns Prestigious ACR Accreditation for Excellence in Cancer Care

Tag: cancer cell

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us